Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas

BACKGROUND: Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogino, Hirokazu, Taylor, Jennie W., Nejo, Takahide, Gibson, David, Watchmaker, Payal B., Okada, Kaori, Saijo, Atsuro, Tedesco, Meghan R., Shai, Anny, Wong, Cynthia M., Rabbitt, Jane E., Olin, Michael R., Moertel, Christopher L., Nishioka, Yasuhiko, Salazar, Andres M., Molinaro, Annette M., Phillips, Joanna J., Butowski, Nicholas A., Clarke, Jennifer L., Oberheim Bush, Nancy Ann, Hervey-Jumper, Shawn L., Theodosopoulos, Philip, Chang, Susan M., Berger, Mitchel S., Okada, Hideho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803342/
https://www.ncbi.nlm.nih.gov/pubmed/34882581
http://dx.doi.org/10.1172/JCI151239
_version_ 1784642850568273920
author Ogino, Hirokazu
Taylor, Jennie W.
Nejo, Takahide
Gibson, David
Watchmaker, Payal B.
Okada, Kaori
Saijo, Atsuro
Tedesco, Meghan R.
Shai, Anny
Wong, Cynthia M.
Rabbitt, Jane E.
Olin, Michael R.
Moertel, Christopher L.
Nishioka, Yasuhiko
Salazar, Andres M.
Molinaro, Annette M.
Phillips, Joanna J.
Butowski, Nicholas A.
Clarke, Jennifer L.
Oberheim Bush, Nancy Ann
Hervey-Jumper, Shawn L.
Theodosopoulos, Philip
Chang, Susan M.
Berger, Mitchel S.
Okada, Hideho
author_facet Ogino, Hirokazu
Taylor, Jennie W.
Nejo, Takahide
Gibson, David
Watchmaker, Payal B.
Okada, Kaori
Saijo, Atsuro
Tedesco, Meghan R.
Shai, Anny
Wong, Cynthia M.
Rabbitt, Jane E.
Olin, Michael R.
Moertel, Christopher L.
Nishioka, Yasuhiko
Salazar, Andres M.
Molinaro, Annette M.
Phillips, Joanna J.
Butowski, Nicholas A.
Clarke, Jennifer L.
Oberheim Bush, Nancy Ann
Hervey-Jumper, Shawn L.
Theodosopoulos, Philip
Chang, Susan M.
Berger, Mitchel S.
Okada, Hideho
author_sort Ogino, Hirokazu
collection PubMed
description BACKGROUND: Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy. METHODS: We conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor. RESULTS: A total of 17 eligible patients were enrolled — 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8(+) T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8(+) T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident–like CD8(+) T cells with effector memory phenotype in the TME after the neoadjuvant vaccination. CONCLUSION: The regimen induced effector CD8(+) T cell response in peripheral blood and enabled vaccine-reactive CD8(+) T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies. TRIAL REGISTRATION: ClinicalTrials.gov NCT02549833. FUNDING: NIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.
format Online
Article
Text
id pubmed-8803342
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-88033422022-02-04 Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas Ogino, Hirokazu Taylor, Jennie W. Nejo, Takahide Gibson, David Watchmaker, Payal B. Okada, Kaori Saijo, Atsuro Tedesco, Meghan R. Shai, Anny Wong, Cynthia M. Rabbitt, Jane E. Olin, Michael R. Moertel, Christopher L. Nishioka, Yasuhiko Salazar, Andres M. Molinaro, Annette M. Phillips, Joanna J. Butowski, Nicholas A. Clarke, Jennifer L. Oberheim Bush, Nancy Ann Hervey-Jumper, Shawn L. Theodosopoulos, Philip Chang, Susan M. Berger, Mitchel S. Okada, Hideho J Clin Invest Clinical Medicine BACKGROUND: Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy. METHODS: We conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor. RESULTS: A total of 17 eligible patients were enrolled — 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8(+) T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8(+) T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident–like CD8(+) T cells with effector memory phenotype in the TME after the neoadjuvant vaccination. CONCLUSION: The regimen induced effector CD8(+) T cell response in peripheral blood and enabled vaccine-reactive CD8(+) T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies. TRIAL REGISTRATION: ClinicalTrials.gov NCT02549833. FUNDING: NIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science. American Society for Clinical Investigation 2022-02-01 2022-02-01 /pmc/articles/PMC8803342/ /pubmed/34882581 http://dx.doi.org/10.1172/JCI151239 Text en © 2022 Ogino et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Medicine
Ogino, Hirokazu
Taylor, Jennie W.
Nejo, Takahide
Gibson, David
Watchmaker, Payal B.
Okada, Kaori
Saijo, Atsuro
Tedesco, Meghan R.
Shai, Anny
Wong, Cynthia M.
Rabbitt, Jane E.
Olin, Michael R.
Moertel, Christopher L.
Nishioka, Yasuhiko
Salazar, Andres M.
Molinaro, Annette M.
Phillips, Joanna J.
Butowski, Nicholas A.
Clarke, Jennifer L.
Oberheim Bush, Nancy Ann
Hervey-Jumper, Shawn L.
Theodosopoulos, Philip
Chang, Susan M.
Berger, Mitchel S.
Okada, Hideho
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
title Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
title_full Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
title_fullStr Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
title_full_unstemmed Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
title_short Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
title_sort randomized trial of neoadjuvant vaccination with tumor-cell lysate induces t cell response in low-grade gliomas
topic Clinical Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803342/
https://www.ncbi.nlm.nih.gov/pubmed/34882581
http://dx.doi.org/10.1172/JCI151239
work_keys_str_mv AT oginohirokazu randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT taylorjenniew randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT nejotakahide randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT gibsondavid randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT watchmakerpayalb randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT okadakaori randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT saijoatsuro randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT tedescomeghanr randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT shaianny randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT wongcynthiam randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT rabbittjanee randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT olinmichaelr randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT moertelchristopherl randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT nishiokayasuhiko randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT salazarandresm randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT molinaroannettem randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT phillipsjoannaj randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT butowskinicholasa randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT clarkejenniferl randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT oberheimbushnancyann randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT herveyjumpershawnl randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT theodosopoulosphilip randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT changsusanm randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT bergermitchels randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas
AT okadahideho randomizedtrialofneoadjuvantvaccinationwithtumorcelllysateinducestcellresponseinlowgradegliomas